



David Assis, MD

Dr. Assis completed his medical school and residency training at Jefferson Medical College in Philadelphia, PA, where he was also a chief resident. He moved to New Haven, CT, to pursue clinical and research expertise in hepatology during his fellowship at Yale University. Dr. Assis also completed a transplant hepatology fellowship. He is now an Assistant Professor of Medicine at Yale, where his clinical and research interests focus on autoimmune liver diseases, including Primary Sclerosing Cholangitis and Autoimmune Hepatitis.



Ulrich Beuers, MD

Dr. Beuers is Head of Hepatology and Professor and Programme Director of Gastroenterology and Hepatology at the Academic Medical Centre (AMC) of the University of Amsterdam. He was awarded his medical and doctoral degree at the University of Freiburg in 1983 and his 'habilitation' (the German extended PhD) at the University of Munich in 1994. After training as an internist, he chose to specialize in gastroenterology and hepatology. Professor Beuers is involved with research in the field of chronic cholestatic and autoimmune liver diseases. His research group has a particular interest in the pathogenesis and therapy of Primary Sclerosing Cholangitis, Primary Biliary Cholangitis, and IgG4-related systemic disease. Professor Beuers is Associate Editor of the Journal of Hepatology, and a member of the editorial boards of various journals, including Hepatology and Gut. He chaired the EASL Clinical Practice Guidelines for the management of cholestatic liver diseases. He is chairman of the Netherlands Association for the Study of the Liver and the Netherlands Education Committee in Gastroenterology and Hepatology and has participated in many advisory boards.



Christopher Bowlus,
MD

Dr. Bowlus' research is focused on the clinical and translational sciences of autoimmune liver diseases, particularly PBC and PSC. His early work focused on the cloning of HLA-encoded genes in the early stages of the Human Genome Project. This work led to collaboration with investigators at the University of Oslo and it continues through the International PSC Study Group. More recently, Dr. Bowlus' research has focused on the genetic basis of PSC in African Americans. He has also been actively involved in the PSC and PBC patient communities, co-organizing the PSC Partners Seeking a Cure National Conference in Sacramento in 2011. He currently serves as Co-Chair of PSC Partners' Scientific/Medical Advisory Committee.





James L. Boyer, MD





Dr. Boyer is Ensign Professor of Medicine and Emeritus Director of the Liver Center at Yale University School of Medicine. He graduated from Haverford College (1958) and the Johns Hopkins University School of Medicine (1962). He is past chairman of the Board of the American Liver Foundation and Mt. Desert Island Biological Laboratory and a current member of the Board of Managers of Haverford College. His research focuses on mechanisms of bile formation and cholestasis, supported by an NIH MERIT award. He is past president of the American and International Associations for the Study of Liver Disease and is recipient of the former organization's Distinguished Achievement Awards.



Myron Brand, MD

Dr. Brand has practiced gastroenterology for 30 years, screening patients for colon cancer, managing complicated diseases of the esophagus and stomach, and treating patients with Crohn's disease, ulcerative colitis and diseases of the liver. He is board-certified in internal medicine and gastroenterology, and he strives to combine "the intellectualism of diagnostic medicine with the ability to provide expert and up-to-date gastroenterological care." Dr. Brand received the Vincent DeLuca Award as outstanding teacher from the Yale gastroenterology section. His group practice offers the advantages of a university practice in a private office setting.

 <p>Jeremy Burke, D.Mus., ALHC</p>	<p>Jeremy Burke is a Senior Learning Consultant with Aetna Group Insurance, supporting Aetna’s Disability and Leave of Absence business. Jeremy has been with Aetna since 2002, spending five years as a claims administrator prior to moving to his current role supporting the training and development of claims staff. Prior to joining Aetna, Jeremy was a music educator and continues to perform as a classical saxophonist. He is currently in the process of scheduling and presenting several lecture recitals intended to help raise awareness of PSC and the need for organ donors. Jeremy’s brother, Philip, introduced him to PSC Partners in 2012.</p>
 <p>Cary A. Caldwell, MD</p>	<p>Dr. Caldwell graduated from Bates College in Maine and the University of Pittsburgh School of Medicine. He completed his Internship and Residency in Internal Medicine at Yale-New Haven Hospital, then a Fellowship in Gastroenterology and Liver Disease at the University of Michigan Medical Center, focusing in Transplant Hepatology. He was a member of the full-time faculty in the Gastroenterology Division at Barnes Hospital and Washington University School of Medicine, and later became co-director of Transplant Hepatology at Barnes. In 1998, he joined the practice of Connecticut Gastroenterology Consultants in New Haven, CT. In 2001 he became part-time faculty at Yale New Haven Transplant Center with an appointment as Clinical Associate Professor of Medicine at Yale School of Medicine. Dr. Caldwell practices Gastroenterology, Hepatology and Transplant Hepatology, and is board certified in both Gastroenterology and Transplant Hepatology. He is a member of the American College of Gastroenterology, American Association for the Study of Liver Disease, and American Society of Transplant. He serves on numerous committees including the Connecticut chapter of the American Liver Foundation and the Donate Life Board.</p>
 <p>Roger Chapman, MD</p>	<p>Dr. Chapman trained in liver disease with Professor Sheila Sherlock at the Royal Free Hospital in London. He has published six books, over 80 book chapters, and 230 original articles, primarily in the field of autoimmune liver disease, Primary Sclerosing Cholangitis, Primary Biliary Cirrhosis and IgG4-related disease. He is a founding member of the International Autoimmune Hepatitis Group. More recently, Dr. Chapman has been involved in the foundation of the International PSC Study Group and the foundation of the British Autoimmune Liver Disease Study Group. He is one of the authors of the current EASL guidelines for cholestatic liver diseases and the first author of the North American AASLD guidelines on the “Management of Primary Sclerosing Cholangitis.” Dr. Chapman was awarded a Fellowship of American Association for the Study of Liver Disease in 2014.</p>

 <p>Olivier Chazouillères, MD</p>	<p>Dr. Chazouillères currently serves as the head of Hepatology Unit at Hopital Saint Antoine, Paris, France and is the coordinator of the Rare Liver Diseases French Network. He is also a former Director of the Department of Digestive Diseases at Hopital Saint Antoine. He has served on several advisory boards, including the French Association for the Study of the Liver and the Scientific Committee of Agence Nationale de Recherche sur le Sida et les Hépatites Virales. His special interests include cholestatic liver diseases such as Primary Sclerosing Cholangitis, other autoimmune liver diseases, and liver transplantation.</p>
 <p>Cindy Dunn</p>	<p>Ms. Dunn began her practice of T'ai Chi Chih® in February 2003, and attained her teacher's accreditation in March 2005. Her teachers include Sandy McAlister and Justin Stone, the originator of T'ai Chi Chih®. She has trained college faculty and staff, young adults, children, senior citizens, and the visually and hearing impaired. Ms. Dunn also teaches seated classes at rehabilitation facilities. She is an instructor of T'ai Chi Chih® at South Plains College in Levelland, Texas. She co-owns and manages Family Vision and Wellness Center in Lubbock, Texas.</p>
 <p>John Eaton, MD</p>	<p>Dr. Eaton graduated from the University of Kansas Medical School and completed his Internal Medicine training at Mayo Clinic in Rochester, Minnesota. As a resident he had the opportunity to work with Dr. Keith Lindor, who helped spark his interest in PSC. He remained at Mayo and went on to complete a Chief Residency and a Gastroenterology Fellowship. Dr. Eaton was the first individual at his institution to accept a unique one-year Clinical Investigator position, which focuses on the care of patients with cholestatic liver disorders and clinical research in this arena. His research focuses on the development of novel biomarkers to predict disease outcomes in PSC and clinical trials.</p>
 <p>Carol Eggers, MSN, NP</p>	<p>Ms. Eggers is a Family and Psychiatric Nurse Practitioner who has been practicing at Yale Digestive Diseases since 2004. She has been practicing and teaching mindfulness meditation since 1998.</p>



Udeme D. Ekong, MD

Dr. Ekong is a board certified Pediatric Gastroenterologist, Hepatologist and Transplant Hepatologist at Yale School of Medicine. Her research interests include understanding determinants of chronic liver allograft dysfunction, specifically, immunological factors contributing to development of post-transplant de novo autoimmune hepatitis; as well as understanding the mechanisms underlying disease pathogenesis in autoimmune hepatitis. Her laboratory is studying the different mechanisms through which regulatory T cells from liver transplant recipients with de novo autoimmune hepatitis differentiate towards a pro-inflammatory phenotype and lose suppressive function. In addition to her laboratory research, Dr. Ekong is also an investigator in several multi-center clinical trials including "Ursodeoxycholic Acid Therapy in Pediatric Primary Sclerosing Cholangitis: A Pilot Withdrawal/Reinstitution Trial" and "Pediatric Primary Sclerosing Cholangitis Outcome Study." Her publications have focused on clinical, histological and immunological outcomes following pediatric liver transplantation, immunological biomarkers predicting donor-specific alloreactivity, immunosuppression withdrawal following pediatric liver transplantation. She is also the author of several book chapters on autoimmune liver diseases in children.



Bertus Eksteen, MD,
PhD

Dr. Eksteen has been a faculty member at the University of Calgary since 2011, as a member of the Liver Unit, the Southern Alberta Liver Transplant Clinic, and the Snyder Institute for Chronic Diseases. His main interests are autoimmune liver and gastrointestinal diseases such as PSC, Autoimmune Hepatitis, and IBD. His research has defined many of the immune pathways that underpin these diseases. He participates in the International PSC Study Group and runs one of the largest PSC clinics in the world. His research includes clinical trials of novel drugs to treat PSC and examining the genes and environmental changes that lead to PSC and IBD. He leads several research consortia, including a large Canadian Institutes of Health Research grant in IBD and PSC.

Dr. Eksteen was born in South Africa, receiving his medical degree at the University of Pretoria. He completed his training in gastroenterology and transplant hepatology at the University of Birmingham, UK in 1996. He spent ten years on the Birmingham liver transplant unit as an MRC Clinician scientist and member of clinical staff, and obtained a PhD in liver immunology in 2007. He was elected a Fellow of the Royal College of Physicians of London, UK in 2011. His published work has appeared in Science, the Journal of Experimental Medicine, Gastroenterology, and Hepatology. His work has received numerous awards.



Karan McBride
Emerick, MD, MSCI

Dr. Emerick is board certified in Pediatric Gastroenterology and Transplant Hepatology. She completed her pediatric residency and pediatric gastroenterology fellowship at The Children's Hospital of Philadelphia. After residency, she joined the pediatric hepatology and transplant team at Children's Memorial Hospital (now Lurie Children's Hospital) of Northwestern University in Chicago for eight years. Her research focused on familial cholestatic diseases. She joined the Connecticut Children's Medical Center in 2006, where she is the Director of the Pediatric Liver Service and an Associate Professor of Pediatrics. She is also affiliated faculty with the Pediatric Liver Transplant program at Yale New Haven Hospital.



James Farrell, MD

Dr. Farrell graduated from medical school at University College, Dublin, and trained in internal medicine at Johns Hopkins Hospital, followed by a gastroenterology fellowship with clinical and molecular biology training at Massachusetts General Hospital and Harvard Medical School. He was trained in advanced interventional endoscopy, including ERCP and endoscopic ultrasound at both Massachusetts General Hospital and Brigham and Women's Hospital, Boston. He is board certified in internal medicine, gastroenterology and clinical pharmacology. In 2001, he joined the UCLA Health System as an interventional endoscopist and to build an endoscopic ultrasound program. Since 2013, Dr. Farrell has led the Yale Center for Pancreatic Diseases at Yale School of Medicine and Yale New Haven Hospital. His current clinical practice is based at the Smilow Cancer Hospital at Yale and involves taking care of patients with all forms of gastrointestinal malignancy, liver, and pancreatic disease, as well as performing interventional endoscopy procedures. He is a clinical translational researcher in pancreatic disease and gastrointestinal cancer, with ongoing research in early pancreatic cancer diagnosis, pancreatic cystic neoplasms, and pancreatic cancer therapeutics and pharmacogenomics.



Dwain Fehon, PsyD

Dr. Fehon is an Assistant Professor within the Department of Psychiatry, Yale School of Medicine and the Director of Behavioral Medicine at Yale-New Haven Hospital. He is a member of Yale-New Haven Transplant Center's liver transplant program and the Yale Cancer Center's palliative care service. Within these programs, Dr. Fehon provides integrated evidence-based psychological support to facilitate coping, resilience, and quality of life for patients living with advanced and life altering illness. His academic interests relate to understanding the psychological, behavioral, and neuropsychiatric comorbidities among individuals with end stage liver disease and cancer, and developing novel therapies to reduce the risk of stress related anxiety and depression.






Brett Fortune, MD




Dr. Fortune is a transplant hepatologist who cares for patients with advanced liver disease at Yale-New Haven Hospital and Yale-New Haven Transplantation Center in New Haven, Connecticut. He helps patients with their complications related to cirrhosis as well as assists patients through the liver transplant evaluation process. In addition, Dr. Fortune also assists patients who have received a liver transplant. His research involves outcomes related to complications from cirrhosis and portal hypertension.



David Goldberg, MD,
MSCE

Dr. Goldberg moved to Philadelphia in 2008 for his training in gastroenterology and transplant hepatology, where he first became interested in PSC. Dr. Goldberg spends 20% of his time doing clinical work taking care of patients with liver disease across the entire spectrum, with a special focus on PSC. The other 80% of his time is spent doing research, which includes analyses of large databases, observational studies, and clinical trials of patients, including PSC.

 <p>Lyle Hawes, PT</p>	<p>Mr. Hawes graduated from the University of Connecticut with a Bachelor of Science in Physical Therapy in 1975. He has over 40 years of experience in the outpatient, short-term rehab, home care, and acute care settings. He has worked with transplant patients in the acute setting for the past ten years.</p>
 <p>Gideon Hirschfield, MD</p>	<p>Dr. Hirschfield is a clinician and academic with a special interest in hepatology, including in particular autoimmune liver disease, as well as the conduct of clinical trials in liver disease. He is well published scientifically and clinically in his field, having made important contributions to the understanding and clinical management of diseases such as primary biliary cholangitis/cirrhosis, primary sclerosing cholangitis and autoimmune hepatitis. He joined Birmingham in 2012 after just over four years in Toronto where he focused heavily on the genetics of autoimmune liver disease. His overarching goal is to continue the translation of scientific advances towards new rational therapies for patients with chronic inflammatory liver diseases.</p>
 <p>Tom Karlsen, MD, PhD</p>	<p>Dr. Karlsen is the leader of the Norwegian PSC Research Center at the Department of Transplantation Medicine, as well as the Section of Molecular Hepatology at the Research Institute of Internal Medicine; altogether comprising three research groups (Experimental liver research, Genomics and metagenomics in inflammatory disorders, and a clinical research group) at Oslo University Hospital Rikshospitalet. Dr. Karlsen works as a full Professor of Internal Medicine at the University of Oslo. Clinically, he works as a senior consultant within transplant hepatology at the Section of Gastroenterology at the Department of Transplantation Medicine at Oslo University Hospital Rikshospitalet. Dr. Karlsen's research experience mainly relates to genetics and disease mechanisms in liver and gut inflammatory diseases, Primary Sclerosing Cholangitis in particular. He is coordinator of the International PSC Study Group and serves as Vice Secretary for the European Association for the Study of the Liver.</p>

 <p>Sylvia Lempit, MSN, APRN</p>	<p>Ms. Lempit is a graduate of the Yale University School of Nursing. She was selected as an AASLD NP Fellow for post-graduate study and had the opportunity to work in Hepatology at the Yale School of Medicine. Since then, Ms. Lempit has focused on liver transplantation and has participated in over 100 liver transplants, including liver donor transplants at the Yale-New Haven Transplantation Center. She derives great reward in educating and empowering patients to achieve improved outcomes in their journey to health and wellness.</p>
 <p>Cynthia Levy, MD</p>	<p>Dr. Levy received her medical degree from Universidade Federal do Rio de Janeiro, Brazil, and completed her residency in Internal Medicine at Jackson Memorial Hospital/University of Miami. She completed a fellowship in Gastroenterology and Hepatology at the Mayo Clinic, Rochester, MN, and subsequently pursued training in Transplant Hepatology at the University of Florida, Gainesville, FL. Prior to coming to the University of Miami, Dr. Levy served as faculty at the Malcolm Randal VAMC and the University of Florida. Dr. Levy currently serves as the program director for the Transplant Hepatology fellowship at the University of Miami, and is the Assistant Director for the Schiff Center for Liver Diseases. Her interests include cholestatic liver diseases of the adult, especially Primary Biliary Cholangitis and Primary Sclerosing Cholangitis, with a focus on clinical trial development.</p>
 <p>Keith D. Lindor, MD</p>	<p>Dr. Lindor is Dean of the College of Health Solutions at Arizona State University (ASU) and Professor of Medicine at Mayo Clinic. Before coming to ASU, he served as Dean of the Mayo Medical School and was Chair in the Division of Gastroenterology and Hepatology at Mayo Clinic. He also served as Editor-In-Chief of <u>Hepatology</u>, and is the President of the American Association for the Study of Liver Diseases. Dr. Lindor's clinical interests include cholestatic liver diseases in adults, particularly Primary Biliary Cholangitis and Primary Sclerosing Cholangitis, as well as Nonalcoholic Steatohepatitis. He received a Bachelor's of Chemistry degree from the University of Minnesota, and his medical degree from Mayo Medical School.</p>



David C. Mulligan, MD

Dr. Mulligan is a multi-organ transplant surgeon who trained at Baylor University with heavy experience in liver transplantation. He joined Mayo Clinic in Arizona, where his team has built a successful liver, kidney, and pancreas transplant program. Dr. Mulligan and his team also established a highly successful living donor liver transplant program with exceptional long-term patient and graft survival rates. He has performed more than 190 living donor liver transplantations. He and his team also developed a successful heart and pediatric liver program with colleagues at Mayo Clinic and Phoenix Children's Hospital. Dr. Mulligan then moved to Yale University, where he has established a patient-centered, collaborative team environment, accompanied by outstanding academic clinical and basic science research. He currently researches novel strategies in immunosuppression and improved biomechanical organ preservation methods to reduce ischemia/reperfusion injury. He also uses 3D bioprinting to collaborate in finding ways to grow new organs from stem cell precursors. Dr. Mulligan is active in multiple national and international transplantation organizations and has led major efforts including creating means to reduce the disparity of access to life-saving livers in the United States.



Dr. Cyriel Y. Ponsioen,
MD, PhD

Dr. Ponsioen was trained as an Internist at the Free University Medical Center in Amsterdam, and as a gastroenterologist at the Academic Medical Center (AMC) in Amsterdam. He defended his doctoral thesis on Etiological and Clinical Studies in Primary Sclerosing Cholangitis. From 2000-2006, he worked as a consultant gastroenterologist in a large teaching hospital. Then, Dr. Ponsioen was appointed senior staff member at the Department of Gastroenterology & Hepatology at the AMC. His clinical and research activities focus on the study of microbiota in inflammatory bowel disease and Primary Sclerosing Cholangitis (PSC). He has built up a research line in epidemiology, disease course, and biomarkers, and he leads a research line looking into the relationship between the gut and the biliary tree. He is currently the Principal Investigator of four international research projects in PSC, including the DILSTENT trial, a randomized trial comparing balloon dilatation versus short-term stenting for dominant strictures in PSC. Within the International PSC Study Group, he currently chairs the Clinical Working Group.



Anne Marie Rivard,
MPH RD CSR CD-N

Ms. Rivard is a clinical dietitian who has been with the Yale-New Haven Transplantation Center for the past ten years. She received her undergraduate nutrition degree from Cornell University and completed her dietetic internship at Brigham and Women's Hospital in Boston, MA. She went on to complete a Masters of Public Health from UMass Amherst. At Yale, she works with kidney, liver, and pancreas transplant patients both pre- and post-transplant, emphasizing the important role nutrition plays in the transplant process.



Manuel Rodriguez-
Davalos, MD, FACS

Dr. Rodriguez received his medical degree from the Anahuac University. He did a year of research in portal hypertension and hepatobiliary surgery at the National Institutes of Health System in Mexico. He was a surgical intern at the Mayo Clinic in Rochester, MN, and completed his surgical training at the Mayo Clinic Hospital in Scottsdale, AZ. In 2003, he joined the Transplant Team at the Recanati-Miller Transplant Institute as a clinical fellow in Multi-Organ Transplant Surgery at Mount Sinai Medical Center in NYC. In 2005 he joined the New York Medical College as Assistant Professor in Surgery. He coordinated the Transplant Fellowship program from 2006-2009 and helped develop the Pediatric Liver Program. He joined the Yale University Transplant Team in 2010.

Dr. Rodriguez has particular interest in adult and pediatric living donor transplants, hepatocellular carcinoma, and portal hypertension. Dr. Rodriguez is pursuing novel means for perfusion and preservation techniques to improve graft quality and expand the donor pool. His current research involves the use of partial grafts and extended criteria for donation in liver transplantation, and preservation techniques for decreasing ischemia-reperfusion injury in intestinal and liver grafts. He collaborates with the Yale School of Engineering to design and test new perfusion devices for intestinal preservation. Dr. Rodriguez was a Member at Large of the UNOS Liver Committee (2012-2014), and has served on numerous other liver transplantation consortia and advisory boards.



Christoph Schramm,
MD

Prof. Schramm has been involved in clinical and basic research on autoimmune liver diseases for many years. He has trained in gastroenterology and hepatology, and is currently holding a foundation chair for rare diseases at the University Medical Center Hamburg-Eppendorf. His scientific focus is on immune regulation in the liver and the pathogenesis of primary sclerosing cholangitis.



Erik Schrupf, MD

Dr. Schrupf is a professor in the Transplant Department at the Institute of Clinical Medicine at the University of Oslo in Oslo, Norway. His primary areas of research interest involve clinical studies in Primary Sclerosing Cholangitis, researching effective means of treatment and diagnosis. He is also a member of the Norwegian PSC Research Center whose goal is to research basic and clinical aspects of PSC. Dr. Schrupf is also a very well published author, having written many articles on several aspects of liver disease and liver transplantation.



Tamar Taddei, MD

Dr. Taddei is Associate Professor of Medicine in the Section of Digestive Diseases at Yale University and staff hepatologist at VA Connecticut Healthcare System. Her clinical interests include benign and malignant neoplasms of the liver and general and transplant hepatology. She directs the Liver Cancer Teams and Tumor Boards at Smilow Cancer Hospital at Yale-New Haven and at the VA Connecticut Healthcare System. Dr. Taddei is building clinical programs at Yale and the VA with a focus on multidisciplinary, integrated care of the patient with liver cancer. The goals of these programs are to contribute to scientific advances in treatment, improve healthcare delivery, decrease the time from diagnosis to treatment, and improve survival in patients with liver cancer. In collaboration with colleagues across a spectrum of disciplines, she is developing and implementing clinical trials, translational projects, and outcome studies at the VA and Yale. Dr. Taddei has been recognized with teaching awards for her commitment to the education of medical students, residents, and fellows.



Mark Topazian, MD

Dr. Topazian is a gastroenterologist and GI endoscopist with expertise in complex endoscopic procedures such as Endoscopic Ultrasound and Endoscopic Retrograde Cholangiopancreatography. He attended Yale Medical School, and completed his postgraduate training at Yale-New Haven Hospital and the University of California, San Francisco. Dr. Topazian has taught at Yale University, and for the past 12 years, has been on staff at Mayo Clinic. Dr. Topazian and his wife, Janet, work regularly at hospitals in both East and West Africa and they have three grown daughters.



Jeffrey C. Weinreb,
MD, FACR, FISMRM,
FSCBT/MR

Dr. Weinreb, is Professor and Vice Chair for Strategic Planning and Innovation in the Department of at Radiology and Biomedical Imaging at the Yale School of Medicine, and Director of the MRI Service at Yale-New Haven Hospital. He has held faculty positions at UT Southwestern Medical School, Columbia College for Physicians and Surgeons, and NYU School of Medicine, where he was Director of MRI for 15 years and led a group that pioneered the development of Body MRI. For more than three decades, Dr. Weinreb has been an innovator in clinical MRI, and he is a leading authority on MRI contrast agents, MRI safety issues, and clinical applications of Body MRI, including the liver. Dr. Weinreb has served as Vice President of the American College of Radiology, Chairman of the ACR Commission on Quality and the ACR Forum, member of the ACR Board of Chancellors, President of the New York Roentgen Society, and President of the SCBT/MR.



John Wysolmerski, MD

Dr. John J. Wysolmerski graduated from the Yale University School of Medicine in 1986. He works in New Haven, CT and specializes in Sports Medicine and Endocrinology, Diabetes & Metabolism. Dr. Wysolmerski is affiliated with Yale New Haven Hospital and is a professor at Yale University School of Medicine.



Kidist K. Yimam, MD

Dr. Yimam is a board-certified transplant hepatologist and medical director of the Autoimmune Liver Disease Program at California Pacific Medical Center. Her clinical research focuses on cholestatic liver diseases and cholangiocarcinoma, with a particular interest in development and validation of prognostic markers of clinical outcomes in PSC.